112 related articles for article (PubMed ID: 20613666)
1. Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?
Hirth RA; Turenne MN; Wheeler JR; Ma Y; Messana JM
Med Care; 2010 Aug; 48(8):726-32. PubMed ID: 20613666
[TBL] [Abstract][Full Text] [Related]
2. Using knowledge of multiple levels of variation in care to target performance incentives to providers.
Turenne MN; Hirth RA; Pan Q; Wolfe RA; Messana JM; Wheeler JR
Med Care; 2008 Feb; 46(2):120-6. PubMed ID: 18219239
[TBL] [Abstract][Full Text] [Related]
3. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network.
Brown J; Josephson M
Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593
[TBL] [Abstract][Full Text] [Related]
7. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
8. When payment systems collide: the effect of hospitalization on anemia in renal dialysis patients.
Turenne MN; Hirth RA; Messana JM; Turner JS; Sleeman KK; Wheeler JR
Med Care; 2010 Apr; 48(4):296-305. PubMed ID: 20195175
[TBL] [Abstract][Full Text] [Related]
9. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
10. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.
Hirth RA; Held PJ; Orzol SM; Dor A
Health Serv Res; 1999 Feb; 33(6):1567-92. PubMed ID: 10029498
[TBL] [Abstract][Full Text] [Related]
11. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.
Monda KL; Joseph PN; Neumann PJ; Bradbury BD; Rubin RJ
BMC Nephrol; 2015 May; 16():67. PubMed ID: 25928734
[TBL] [Abstract][Full Text] [Related]
12. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
13. Managing anemia in for-profit dialysis chains: when ethics and business conflict.
Coyne DW
Semin Dial; 2009; 22(1):18-21. PubMed ID: 19250444
[TBL] [Abstract][Full Text] [Related]
14. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
[TBL] [Abstract][Full Text] [Related]
15. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
[TBL] [Abstract][Full Text] [Related]
16. Identifying cost management strategies in dialysis clinics: sustainable savings with positive outcomes.
West TD; Gupta M; Balas EA; West DA
Am J Manag Care; 2002 May; 8(5):449-60. PubMed ID: 12019597
[TBL] [Abstract][Full Text] [Related]
17. Anemia: dialysis patients experiences.
Schatell D; Witten B
Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
[No Abstract] [Full Text] [Related]
18. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study.
Burnier M; Douchamps JA; Tanghe A; Demey J; Perrault L; Foster CE; Robbins S
J Med Econ; 2009 Jun; 12(2):77-86. PubMed ID: 19450138
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of case-mix adjusting the dialysis composite rate.
Hirth RA; Roys EC; Wheeler JR; Messana JM; Turenne MN; Saran R; Pozniak AS; Wolfe RA
J Am Soc Nephrol; 2005 May; 16(5):1172-6. PubMed ID: 15800122
[TBL] [Abstract][Full Text] [Related]
20. Provider monitoring and pay-for-performance when multiple providers affect outcomes: An application to renal dialysis.
Hirth RA; Turenne MN; Wheeler JR; Pan Q; Ma Y; Messana JM
Health Serv Res; 2009 Oct; 44(5 Pt 1):1585-602. PubMed ID: 19555398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
